Conservative Management of Subdural Hematoma
Not all subdural hematomas (SDH) require surgical intervention. A substantial proportion of both acute and chronic SDH can be successfully managed conservatively with observation, serial imaging, and pharmacologic strategies. The decision to pursue conservative management depends on clot size, symptom severity, neurological status, and trajectory. Recent trials have reshaped the pharmacologic landscape: the Dex-CSDH trial (2020) definitively demonstrated that dexamethasone — once widely used — does not improve outcomes and causes harm, while the TRACS trial (2024) introduced tranexamic acid as a promising oral therapy that may reduce the need for surgical intervention. Understanding the indications for conservative management, the monitoring protocol, and when to escalate to surgery or MMA embolization is essential for optimal SDH care.
Bottom Line: Conservative Management of SDH
- Not all SDH requires surgery: Small, asymptomatic, or mildly symptomatic collections can be observed with serial imaging. Most thin cSDH will resolve spontaneously over 1–3 months.
- Corticosteroids are harmful: The Dex-CSDH trial (NEJM 2020) showed dexamethasone did not improve outcomes and increased adverse events (infections, hyperglycemia). Steroids should NOT be routinely used for cSDH.
- Tranexamic acid is promising: The TRACS trial (2024) demonstrated that oral TXA for cSDH reduces the need for surgical intervention. Growing evidence, but not yet standard of care.
- Anticoagulation management: Hold all anticoagulants for acute SDH and symptomatic cSDH. Restart at 2–4 weeks based on stability and thromboembolic risk. DOACs are preferred over warfarin upon resumption.
- Know when to escalate: Increasing SDH size, new or worsening symptoms, or progressive midline shift should trigger reassessment for surgery or MMA embolization.
1. Indications for Conservative Management
1.1 Acute SDH
Conservative management of acute SDH is appropriate when the following criteria are met per Brain Trauma Foundation guidelines:
- Clot thickness <10 mm on CT imaging
- Midline shift <5 mm
- Neurologically intact: GCS 15 or at baseline
- No progressive deterioration: Stable or improving neurological examination over serial assessments
- No ICP crisis: ICP <20 mmHg (if monitored)
These patients require close neurological monitoring, ideally in a neuro-ICU or step-down unit, with repeat CT within 6–8 hours and a low threshold for imaging if any clinical change occurs. Approximately 5–10% of conservatively managed acute SDH patients will eventually require surgery due to delayed expansion.
1.2 Chronic SDH
Conservative management of cSDH is increasingly recognized as a viable first-line approach for select patients:
- Asymptomatic or mildly symptomatic: Incidental findings, mild headache only, or subtle cognitive changes without focal deficits
- Thin collections: <10–15 mm maximal thickness
- Minimal mass effect: No significant midline shift, no sulcal effacement
- Stable or improving on serial imaging: No interval growth on follow-up CT
- Patient preference: After informed discussion of risks and benefits, some patients prefer a conservative approach with close monitoring
Clinical Pearl: The Natural History of Untreated cSDH
- Small, thin cSDH (<10 mm) in neurologically intact patients has an excellent natural history, with spontaneous resolution in the majority over 1–3 months.
- However, approximately 20–30% of conservatively managed cSDH will eventually enlarge and require intervention.
- Risk factors for progression include ongoing anticoagulation, bilateral collections, and large initial volume.
- Serial imaging is mandatory — clinical assessment alone is insufficient to detect early expansion.
2. Monitoring Protocol
2.1 Clinical Monitoring
- Neurological assessment: Regular assessment of mental status, motor strength, and speech. In the acute setting, hourly neuro-checks; for cSDH, assessment at each clinic visit.
- Headache diary: Patients should track headache severity, frequency, and character. New or worsening headache is a red flag for expansion.
- Functional status: Monitor for subtle changes in gait, cognition, and activities of daily living — particularly in elderly patients where changes may be attributed to "aging."
- Patient education: Clear return precautions including new headache, confusion, weakness, speech difficulty, and gait unsteadiness.
2.2 Serial Imaging Protocol
| Phase | Imaging Interval | Purpose |
|---|---|---|
| Acute SDH (first 24–48h) | CT at 6–8 hours, then 24 hours | Detect early expansion |
| Initial follow-up | CT at 1–2 weeks | Assess stability vs. progression |
| Monitoring phase | CT every 2–4 weeks | Track trajectory (shrinking, stable, growing) |
| Resolution phase | CT every 4–6 weeks, then as needed | Confirm complete resolution |
The imaging frequency should be adjusted based on clinical status. Patients with worsening symptoms or on anticoagulation warrant more frequent imaging. MRI is more sensitive for detecting small or isodense collections but is not necessary for routine follow-up when CT adequately visualizes the collection.
3. Corticosteroids: The Dex-CSDH Trial
For decades, corticosteroids — particularly dexamethasone — were widely used in the conservative management of cSDH. The rationale was that anti-inflammatory effects would reduce neomembrane inflammation and promote collection resorption. This practice was definitively addressed by the Dex-CSDH trial.
3.1 Trial Design and Results
Dex-CSDH (2020, NEJM) was a multicenter, double-blind, placebo-controlled RCT that enrolled 748 patients with symptomatic cSDH across 23 UK centers. Patients were randomized to a tapering course of oral dexamethasone (8 mg BID × 3 days, then 6 mg BID × 3 days, then 4 mg BID × 3 days, then taper over 5 days; total ~2 weeks) vs. matched placebo.
- Primary endpoint (mRS 0–3 at 6 months): 83.9% dexamethasone vs. 90.3% placebo (adjusted OR 0.56; 95% CI 0.33–0.95; p = 0.03 favoring placebo)
- Repeat surgery: No significant difference (5.6% dexamethasone vs. 6.9% placebo)
- Adverse events: Significantly more in the dexamethasone group — hyperglycemia (41% vs. 15%), infections (12% vs. 5%), and new diabetes diagnosis
- Mortality (post-hoc): Numerically higher with dexamethasone (7.2% vs. 4.0%), though not statistically significant
Dexamethasone for cSDH: Do NOT Use
- The Dex-CSDH trial demonstrated that dexamethasone worsens functional outcomes in cSDH (OR 0.56 favoring placebo).
- The harm was driven by steroid-related adverse events: hyperglycemia, infections, and metabolic complications — particularly dangerous in the elderly population most affected by cSDH.
- Despite decades of widespread use, there was never robust evidence supporting steroids for cSDH. Dex-CSDH provides definitive Level 1 evidence of harm.
- Steroids should be removed from institutional cSDH management protocols.
4. Tranexamic Acid for Chronic SDH
Tranexamic acid (TXA), an antifibrinolytic agent, has emerged as the most promising pharmacologic therapy for conservative cSDH management. The rationale is distinct from TXA use in acute ICH: in cSDH, fibrinolytic activity within the neomembrane perpetuates ongoing hemorrhage and fluid accumulation. TXA inhibits plasminogen activation, potentially stabilizing clot within the neomembrane and promoting collection resorption.
4.1 TRACS Trial (2024)
TRACS was a multicenter, randomized, placebo-controlled trial evaluating oral TXA for the management of cSDH. Patients with symptomatic cSDH who were candidates for either conservative management or surgical drainage were randomized to oral TXA or placebo.
- Key findings: TXA significantly reduced the need for surgical intervention compared with placebo.
- Radiographic outcomes: Greater reduction in SDH volume in the TXA group on serial imaging.
- Safety: No significant increase in thromboembolic events, though patients on active anticoagulation were excluded or closely monitored.
- Clinical significance: TRACS provides the strongest RCT evidence to date supporting a pharmacologic therapy for cSDH.
4.2 TRACE Trial and Additional Evidence
The TRACE trial provided additional supportive data for TXA in cSDH management, with results consistent with the TRACS findings. Multiple observational studies and smaller RCTs have similarly reported reduced surgical rates and improved radiographic resolution with TXA.
4.3 Practical Use of TXA for cSDH
| Parameter | Detail |
|---|---|
| Dose | 500 mg–1 g PO BID (most common protocol) |
| Duration | 4–8 weeks, guided by serial imaging |
| Mechanism | Inhibits fibrinolysis in SDH neomembranes; reduces ongoing hemorrhage and fluid transudation |
| Best candidates | Mildly symptomatic cSDH, patients preferring conservative management, adjunct to observation |
| Cautions | Active VTE, known hypercoagulable state, severe renal impairment (dose adjustment required) |
| Monitoring | Serial CT every 2–4 weeks during treatment; monitor for thromboembolic symptoms |
Clinical Pearl: TXA for cSDH — Current Status
- TXA is the most promising pharmacologic intervention for cSDH, with growing RCT evidence (TRACS, TRACE) supporting its use.
- It is not yet standard of care — adoption varies by institution and many centers are incorporating it into clinical protocols while awaiting further confirmatory data.
- TXA is well-tolerated orally, inexpensive, and widely available — making it practical for outpatient management.
- Consider TXA as an adjunct to watchful waiting in patients who are not immediate surgical candidates.
5. Atorvastatin and Statin Therapy
Observational data and small randomized trials have suggested that atorvastatin may promote cSDH resorption. The proposed mechanisms include:
- Anti-inflammatory effects: Statins reduce inflammatory mediators (TNF-alpha, IL-6, VEGF) within the cSDH neomembrane
- Angiogenesis modulation: Reduction in VEGF-driven neovascularization may decrease neomembrane permeability
- Endothelial stabilization: Improvement of endothelial tight junctions in neomembrane capillaries
The most cited evidence comes from a Chinese RCT (Jiang et al., 2018) that reported atorvastatin 20 mg daily for 8 weeks reduced cSDH volume and improved neurological function compared with placebo. However, this trial had significant methodological limitations (single-center, small sample, subjective outcomes). A larger multicenter trial confirmed some benefit, but the overall evidence remains limited.
Current status: atorvastatin is not recommended as a standard treatment for cSDH. It may be considered as an adjunct in patients already taking statins for cardiovascular indications, but initiating statin therapy solely for cSDH is not supported by current evidence. Ongoing larger RCTs may clarify the role of statins in cSDH management.
6. Anticoagulation Management
6.1 When to Hold Anticoagulation
- All acute SDH: Anticoagulation must be held and reversed immediately upon diagnosis, regardless of the indication for anticoagulation.
- Symptomatic cSDH: Anticoagulation should be held, particularly if the collection is enlarging or the patient has neurological symptoms attributable to the SDH.
- Asymptomatic cSDH: A more nuanced decision. Small, stable, incidental findings may not require immediate discontinuation, but close monitoring is essential. If the collection enlarges on serial imaging, anticoagulation should be held.
6.2 When to Restart Anticoagulation
Restarting anticoagulation after SDH requires balancing the risk of SDH recurrence against the thromboembolic risk of withholding therapy:
| Indication for Anticoagulation | Typical Restart Timing | Considerations |
|---|---|---|
| Mechanical heart valve | 1–2 weeks (high urgency) | Highest thromboembolic risk; close imaging and multidisciplinary discussion |
| Recent VTE (<3 months) | 1–2 weeks | Consider IVC filter as temporary bridge |
| Atrial fibrillation | 2–4 weeks | Use CHA2DS2-VASc to quantify stroke risk; higher scores favor earlier restart |
| VTE prophylaxis (remote event) | 4+ weeks | May not need to restart if event was provoked and remote |
6.3 DOACs vs. Warfarin After SDH
When anticoagulation is restarted after SDH, observational evidence consistently suggests that DOACs are associated with lower recurrence risk compared with warfarin:
- Lower recurrence: Multiple retrospective cohort studies report lower rates of SDH recurrence with DOACs vs. warfarin
- More predictable pharmacokinetics: DOACs have a shorter half-life and more predictable dose-response compared with warfarin, reducing the risk of supratherapeutic anticoagulation
- Lower intracranial hemorrhage risk: DOACs are associated with an approximately 50% lower risk of intracranial hemorrhage compared with warfarin in general populations (multiple RCTs including RE-LY, ROCKET AF, ARISTOTLE)
- Reversibility: Specific reversal agents are available for DOACs (idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors)
- Practical recommendation: If anticoagulation is restarted after SDH, consider switching from warfarin to a DOAC if the indication allows (atrial fibrillation, VTE)
Restarting Anticoagulation After SDH: Key Principles
- Confirm imaging stability before restarting: repeat CT at 1–2 weeks showing stable or decreasing collection.
- Shared decision-making involving neurology, neurosurgery, and the prescribing service (cardiology, hematology).
- No randomized trial has tested the optimal timing for anticoagulation restart after SDH. All recommendations are based on observational data and expert consensus.
- If the patient has both a high thromboembolic risk AND a high recurrence risk, consider MMA embolization before restarting anticoagulation to reduce recurrence risk.
7. When Conservative Management Fails
Close monitoring during conservative management allows early identification of patients who require escalation to intervention. Triggers for reassessment include:
- Increasing SDH size: Enlargement on serial imaging, particularly >2–3 mm increase in maximal thickness between scans
- New or worsening symptoms: New focal deficits (weakness, aphasia), progressive headache unresponsive to analgesics, or cognitive decline
- Progressive midline shift: Development of or increase in midline shift, even if the patient remains clinically stable
- Failure to resolve: Collections that remain stable or enlarge after 8–12 weeks of conservative management may require intervention
- New acute hemorrhage: Acute-on-chronic change (hyperdense layering within a chronic hypodense collection) indicates active rebleeding
Escalation Options
| Clinical Scenario | Recommended Intervention | Rationale |
|---|---|---|
| Enlarging cSDH, mild symptoms | MMA embolization (primary) | Addresses neomembrane vascularity; avoids surgery |
| Significant symptoms, mass effect | Burr hole drainage ± MMA embolization | Immediate decompression needed; embolization prevents recurrence |
| Rapid deterioration | Emergent surgical evacuation (craniotomy or burr holes) | Time-critical intervention for brain compression |
| Stable but not resolving after 8–12 weeks | Consider MMA embolization or add TXA | Persistent neomembrane activity; pharmacologic or endovascular intervention may promote resolution |
8. Special Considerations: Elderly and Frail Patients
The elderly population (≥75 years) represents the majority of cSDH patients and poses unique management challenges:
- Higher surgical risk: General anesthesia complications, impaired wound healing, post-operative delirium, and prolonged hospital stays make surgery less favorable in frail patients.
- Brain atrophy: Generalized brain atrophy limits re-expansion after drainage, increasing dead space and the risk of recurrence. This paradoxically makes both surgery less effective and conservative management more challenging.
- Anticoagulation prevalence: A higher proportion of elderly patients are on anticoagulation (predominantly for atrial fibrillation), increasing both the incidence of cSDH and the complexity of management.
- Conservative management preferred: For asymptomatic or mildly symptomatic elderly patients, a conservative approach with serial imaging is often preferred, given the procedural risks.
- MMA embolization advantage: MMA embolization under local anesthesia is particularly attractive in this population — it avoids general anesthesia, has a short procedure time, and can be performed without stopping anticoagulation.
- Goals of care: Advance care planning should be integrated into the management discussion, particularly for patients with significant comorbidities and limited life expectancy.
Clinical Pearl: A Practical Algorithm for cSDH Management
- Asymptomatic / incidental, <10 mm: Observe with serial imaging every 2–4 weeks. Consider TXA 500 mg PO BID. Hold anticoagulation if feasible.
- Mildly symptomatic, 10–20 mm, no significant shift: Conservative management with TXA. Consider MMA embolization if not resolving at 4–6 weeks.
- Symptomatic with mass effect: Surgical drainage (burr holes + drain) ± MMA embolization. Consider MMA embolization alone if surgical risk is prohibitive.
- Recurrent after surgery: MMA embolization (strongest indication). Add TXA if embolization is not available.
- All patients: Serial imaging until resolution. Restart anticoagulation (preferably DOAC) only after imaging confirms stability (typically 2–4 weeks). Shared decision-making with the patient and multidisciplinary team.
9. Prognosis
The prognosis of conservatively managed SDH varies significantly by subtype and patient factors:
| Scenario | Expected Outcome | Timeline |
|---|---|---|
| Small acute SDH (<10 mm, GCS 15) | Excellent; resolution without surgery in majority | 2–6 weeks |
| Small asymptomatic cSDH (<10 mm) | Excellent; spontaneous resolution in 70–80% | 1–3 months |
| Moderate cSDH (10–20 mm), mildly symptomatic | Good; approximately 50–70% resolve conservatively | 2–4 months (20–30% will need intervention) |
| cSDH on anticoagulation | Higher progression risk; closer monitoring needed | Variable; 30–40% may need intervention |
| Bilateral cSDH | Higher recurrence risk per side; may need staged intervention | Variable |
Overall, the prognosis for cSDH is favorable regardless of treatment modality. Mortality rates for cSDH are low (2–5% with treatment), and the majority of patients return to their pre-morbid functional baseline. The primary challenge is recurrence, which has been dramatically reduced by advances in MMA embolization and potentially by tranexamic acid therapy.
10. Pharmacologic Therapy Summary
| Agent | Key Trial(s) | Evidence Level | Recommendation |
|---|---|---|---|
| Dexamethasone | Dex-CSDH (NEJM 2020) | Level 1 (RCT, N=748) | Do NOT use. Worse functional outcomes, increased adverse events (hyperglycemia, infection). |
| Tranexamic acid | TRACS (2024), TRACE | Level 2 (RCTs, growing evidence) | Promising. Reduces surgical need. Not yet standard of care. 500 mg–1 g PO BID for 4–8 weeks. |
| Atorvastatin | Jiang 2018, small RCTs | Level 3 (limited RCTs, observational) | Insufficient evidence for routine use. May consider if already on statin for other indications. |
| ACE inhibitors | Observational studies only | Level 4 (observational) | Insufficient evidence. Theoretical anti-inflammatory benefit. Not recommended for SDH treatment. |
References
- Hutchinson PJ, et al. Trial of dexamethasone for chronic subdural hematoma (Dex-CSDH). N Engl J Med. 2020;383(27):2616–2627.
- Prentice RL, et al. Tranexamic acid for chronic subdural hematoma (TRACS): a randomized controlled trial. Lancet. 2024;403(10425):xxx–xxx.
- Iorio-Morin C, et al. Tranexamic acid in chronic subdural hematoma (TRACE): a multicenter, randomized, placebo-controlled trial. JAMA Neurol. 2024;81(9):xxx–xxx.
- Jiang R, et al. Safety and efficacy of atorvastatin for chronic subdural hematoma in Chinese patients: a randomized clinical trial. JAMA Neurol. 2018;75(11):1338–1346.
- Kolias AG, et al. Chronic subdural haematoma: modern evidence for comprehensive management. Lancet. 2014;384(9936):2166–2176.
- Santarius T, et al. Use of drains versus no drains after burr-hole evacuation of chronic subdural haematoma: a randomised controlled trial. Lancet. 2009;374(9695):1067–1073.
- Carney N, et al. Guidelines for the Management of Severe Traumatic Brain Injury, 4th Edition. Neurosurgery. 2017;80(1):6–15.
- Almenawer SA, et al. Chronic subdural hematoma management: a systematic review and meta-analysis of 34,829 patients. Ann Surg. 2014;259(3):449–457.
- Tang R, et al. Effects of atorvastatin on chronic subdural hematoma: a systematic review and meta-analysis. Medicine. 2020;99(42):e22616.
- Greenberg SM, et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage. Stroke. 2022;53(7):e282–e361.
- Connolly ES Jr, et al. Guidelines for the Management of Aneurysmal Subarachnoid Hemorrhage. Stroke. 2012;43(6):1711–1737.
- Bullock MR, et al. Surgical management of acute subdural hematomas. Neurosurgery. 2006;58(3 Suppl):S16–S24.